Pharma News

The U.S. Food and Drug Administration today approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

Ibuprofen, a common over-the-counter drug used to relieve pain and fever, could hold the keys to a longer healthier life, according to a study by researchers at the Buck Institute for Research on Aging. Publishing in PLoS Genetics on December 18th, scientists showed that regular doses of ibuprofen extended the lifespan of yeast, worms and fruit flies.

Central Drugs Standard Control Organization (CDSCO) investigated a Pune based hospital after receiving compliant against hospital that they are performing unethical stem cell clinical trial and patients are highly charged for unapproved and illegal transplants.

In two new studies, international research teams including NIAID scientists describe how certain genetic mutations make malaria-causing parasites resistant to artemisinin, a key drug for treating the disease. The findings are published in the Dec. 11, 2014, online issue of Science.

Department of Health and Family Welfare proposes to implement a Central Sector Scheme for Strengthening the Central Drugs Standard Control Organisation (CDSCO); and State Drug Regulatory System during the residual period of Twelfth Five Year Plan (2012 - 2017) at an estimated cost of Rs.900 crore and Rs.850 crore (excluding States’ share) respectively.

(Business Wire India); Tata Capital, the financial services arm of the Tata Group, as part of its Do Right initiative, concluded a first-of-its-kind Survey to identify the major challenges facing our country today. The “Tata Capital India4India” Survey was conducted online on the website – doright.in & saw voting from more than 5000 respondents across the country. The top five challenges that emerged as the most concerning for the Indian public were Basic Healthcare, Illiteracy, Child Rights, Women Empowerment and Food Scarcity.

IP Addendum-2015 to IP-2014 has been released on 28.11.2014 by Sh. Lov Verma, Secretary Health & Family Welfare and Chairman, India Pharmacopoeia Commission in the presence of senior officers of Ministry of Health & Family Welfare and Scientific Staff of IP Commission.

AstraZeneca announced that MOVENTIG® (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved in the European Union (EU).

Harvard Stem Cell Institute (HSCI) researchers have taken what they describe as “the first step toward a pill that can replace the treadmill” for the control of obesity, though that shift, of course, would not provide all of the many benefits of exercise.

[adsense:336x280:8701650588]